Oregon Health and Science University
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Oregon Health and Science University sits in the top decile of US sponsors by registered trial count (#67 of 15,742 sponsors by registered trial count).
Oregon Health and Science University: 546 sponsored US clinical trials, 91 recruiting.
Oregon Health and Science University sponsors 546 registered US clinical trials on ClinicalTrials.gov, 91 of them currently recruiting, and 370 completed. 73 of these trials are in Phase 3-4 (later-stage) and 92 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 6 trials.
Top-decile sponsor footprint
Oregon Health and Science University ranks in the top decile of sponsors by registered trial count (#67 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
370 of 420 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
546 total, page 10 of 11
Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy
NCT00962429
Low Fat Diet and Multiple Sclerosis
NCT00852722
Ghrelin Regulation and Structure: Effect of Thiazolidinedione Therapy on Ghrelin
NCT00843791
Mechanistic Pathways of Mindfulness Meditation in Post-traumatic Stress Disorder.
NCT00778960
A Translational Approach to Gitelman Syndrome
NCT00822107
Home-based Self-delivered Mirror Therapy for Phantom Limb Pain
NCT00827294
VANOS Cream and Skin Barrier Function
NCT00819507
Clinical Trial Examining Effects of Monosodium Glutamate (MSG) on Irritable Bowel Syndrome (IBS) and Fibromyalgia (FM)
NCT00829218
Rehabilitation of the Upper Extremity With Enhanced Proprioceptive Feedback Following Incomplete Spinal Cord Injury
NCT00833105
The Effects of Treadmill Versus Agility Training in Parkinson's Disease
NCT00982709
Cognitive Behavioral Therapy for Depression in Parkinson's Disease
NCT00810628
Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration
NCT00805233
Evaluation of Surgical Treatment on Pain and Disability for Chronic, Non-healing Rib Fracture
NCT00774618
Neurocognitive and Metabolic Effects of Mild Hypothyroidism
NCT00565864
Study of Ultrasound of the Eye for Children With Suspected Shunt Failure
NCT00743457
Study of Pathways Curriculum for Use With WPD
NCT00788814
DNA Microarray Study of Pancreas Cancer
NCT00680420
Circadian Effects of Escitalopram
NCT01214044
Evaluation of Ultrasonic Neuroma Size With Residual Limb Pain in Above-Knee Amputees
NCT00686764
Clinic-Based AMES Treatment of Stroke
NCT00847704
Ghrelin Regulation and Structure: Effect of Diet Composition on Ghrelin
NCT00694512
Vitamin D to Prevent Autism in Newborn Siblings
NCT01366885
Hemodynamics and Extravascular Lung Water in Acute Lung Injury
NCT00624650
The Effects of a Prostaglandin Inhibitor on Ovulation and the Menstrual Cycle
NCT00614406
Elucidating the Role of Microvascular Dysfunction in Heart Disease in Women
NCT00663520
Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis
NCT00525902
Clinical Trial of Acamprosate for Tinnitus
NCT00596531
Endometrial Biopsy Instrument Comparison Study
NCT00613925
Comparative Study of Laparoscopic Versus Open Appendectomy in Children
NCT00554008
The Influence of Probiotics on Vancomycin-Resistant Enterococcus
NCT00591474
Study of Endoscopic Barrett's Esophagus Diagnosis
NCT00591461
Lutein and Alzheimer's Disease Study
NCT00596024
Meditation or Education for Alzheimer Caregivers
NCT00558402
Safety Study Of N-Acetylcysteine For Prevention Of Contrast Induced Nephropathy In Patients w/Stage 3 Renal Failure
NCT00575419
Group Therapy Program for Women With Physical Disabilities
NCT00618566
Metabolic Consequences of CPT-1 Deficiency
NCT00653666
Lidocaine and Pain Management in First Trimester Abortions
NCT00613821
Centella Asiatica Selected Triterpenes (CAST) for Diabetic Neuropathy
NCT00608439
Body Worlds 3 Nutrition Display
NCT00669500
Misoprostol With Intrauterine Device Insertion
NCT00613366
Hip Osteoarthritis: Effects of Exercise Programs on Pain and Disability
NCT00682617
A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD
NCT00469352
A Study of Continuous Oral Contraceptives and Doxycycline
NCT00480532
Immediate Versus Delayed Intrauterine Device (IUD) Insertion Following First Trimester Suction Aspiration Procedures
NCT00562276
Hormonal Contraception and Vaginal Health
NCT00612508
Intrauterine Lidocaine Infusion for Essure Sterilization Procedures
NCT00613834
Evaluating the Effects of Supplemental Vitamin C on Infant Lung Function in Pregnant Smoking Women
NCT00632476
How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics
NCT00667732
Obesity and Memory, mRNA, Body Composition, Comorbidity Scale
NCT00531505
Immunologic Response to Negative Cognition in Persons With Chronic Pain
NCT00677911
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 52 |
| Phase 2 | 40 |
| Phase 3 | 6 |
| Phase 4 | 67 |
Therapeutic Areas
What is open in the Oregon Health and Science University pipeline
91 recruiting of 546 indexed (17% open); 370 completed (68%).
Phase mix: 73 late (III/IV) vs 92 early (I/II) (balanced across stages).
Top condition: Obesity (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Oregon Health and Science University: open-pipeline peers nationwide
Peers matched on 546 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Oregon Health and Science University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 546 trials (± recruiting share)
- Ohio State University · 552 trials · 21% recruiting
- Amgen · 558 trials · 10% recruiting
- Merck Sharp & Dohme · 558 trials · 22% recruiting
- Virginia Commonwealth University · 558 trials · 14% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
- Akamis Bio · 17% recruiting · 6 trials
- Angiodynamics · 17% recruiting · 12 trials
Related
What to do with this Oregon Health and Science University page
546 registered trials is a research-attention snapshot, not an endorsement of Oregon Health and Science University or any single study.
- 91 of Oregon Health and Science University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition Oregon Health and Science University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Oregon Health and Science University pipeline card: 546 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.